Eli Lilly LLY secured a significant milestone on Friday when it became the first company in the healthcare space to reach $1 ...

Zepbound and Mounjaro posted triple-digit revenue growth, making Lilly the first health industry giant to reach a ...

Both semaglutide and tirzepatide are associated with improvements in quality of life for adults with obesity, though ...

Eli Lilly’s market capitalisation hit the $1tn mark in the past week, becoming the first healthcare company in the world to ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by ...

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...

More than 90% of women with polycystic ovary syndrome achieved at least 10% total weight loss after 10 months of tirzepatide ...

CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs ...

Eli Lilly just hit a new kind of orbit. Investors pushed Eli Lilly past the $1 trillion mark on Friday as its shares climbed ...

Eli Lilly became the first healthcare company to hit a $1 trillion valuation (briefly on Nov. 21) MONDAY, Nov. 24, 2025 ...